AbbVie continues to project low single-digit growth through 2030 as it expands its immunology franchise and makes a major ...
Johnson & Johnson (NYSE:JNJ) is included among the 14 Best Dividend Growth Stocks to Buy and Hold in 2026. On December 30, ...
Singapore’s stock market offers banks, which are among the best in the world, and a large and tightly regulated REIT market. These are perfect for local investors to invest within their circle of ...
The S&P 500 Dividend Aristocrats tracks companies in the index that have raised dividends every year for at least 25 straight ...
The Chosun Ilbo on MSN
Samsung Epis Holdings to Expand into New Drug Development
President Kim Kyung-ah of Samsung Epis Holdings held a press briefing on the 14th at the JP Morgan Healthcare Conference in ...
Thursday, January 8, 2026The Zacks Research Daily presents the best research output of our analyst team. Today's Research ...
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the ...
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
Throughout 2025, AbbVie’s Skyrizi and Johnson & Johnson’s Tremfya were mainstays at the top of the monthly TV drug ad ...
Both Skyrizi and its cousin Rinvoq have landed in the annual top three, in varying positions, since 2022. That was once again the case in 2025, when Skyrizi retained its place at the top and Rinvoq ...
Johnson & Johnson JNJ announced that the European Commission (EC) has approved an expanded use of its blockbuster psoriasis drug, Tremfya, in children. Tremfya is now approved to treat pediatric and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback